Huub H van Rossum, Stefan Holdenrieder, Bart E P B Ballieux, Tony C Badrick, Yeo-Min Yun, Chuanbao Zhang, Dina Patel, Marc Thelen, Junghan Song, Nathalie Wojtalewicz, Nick Unsworth, Hubert W Vesper, Wei Cui, Lakshmi V Ramanathan, Catharine Sturgeon, Qing H Meng
BACKGROUND: The harmonization status of most tumor markers (TMs) is unknown. We report a feasibility study performed to determine whether external quality assessment (EQA) programs can be used to obtain insights into the current harmonization status of the tumor markers α-fetoprotein (AFP), prostate specific antigen (PSA), carcinoembryonic antigen (CEA), cancer antigen (CA)125, CA15-3 and CA19-9. METHODS: EQA sample results provided by 6 EQA providers (INSTAND [Germany], Korean Association of External Quality Assessment Service [KEQAS, South Korea], National Center for Clinical Laboratories [NCCL, China], United Kingdom National External Quality Assessment Service [UK NEQAS, United Kingdom], Stichting Kwaliteitsbewaking Medische Laboratoriumdiagnostiek [SKML, the Netherlands], and the Royal College of Pathologists of Australasia Quality Assurance Programs [RCPAQAP, Australia]) between 2020 and 2021 were used...
February 22, 2024: Clinical Chemistry